ArticleJournal of obstetrics and gynaecology of India2025
Prevalence of Mismatch Repair Gene Defects by Means of Immuno-histochemistry Staining for MMR Proteins in Endometrial Cancer.
Article in Journal of obstetrics and gynaecology of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In India, the incidence of uterine cancer is 17,420 per year. Presence of mismatch repair genes is one of the risk factors which can cause microsatellite instability in DNA leading to hereditary syndromes as well as sporadic cancer. In the present study, we aim to determine the prevalence of MMR gene mutations by IHC staining for MMR proteins in endometrial cancer. We further aim to corelate various clinic-pathological features with mismatch repair gene defect (MMRd) cancers and to determine its effects recurrence and survival in endometrial cancer. Materials and Methods: This is an ambispective study of a retrospectively selected cohort followed up prospectively. It was conducted in the Department of Gynaecological Oncology, AIMS. The cohort was evaluated for the four MMR proteins via IHC staining, and their various clinic-pathological factors were studied. Also, the factors affecting their recurrence free survival (RFS) and overall survival (OS) were observed. Results: The prevalence of MMR loss in endometrial cancer patients was 31.34%. Most common loss of MMR gene was MLH1 and PMS 2 (57.14%). We did not find any significant differences pertaining to age, BMI, menstrual status, family history and second malignancies in both groups of endometrial cancers. While comparing the histopathological characteristics, no significant difference was found regarding to histopathology, stage, type, grade, P53 status, tumour size, lymph node involvement and LVSI status. No significant difference was seen between two groups in RFS and OS. Conclusion: We found a significant proportion of endometrial cancers with defective MMR genes in Indian population. We did not find any correlation of MMR to the various clinical and histopathological factors that we analysed. MMRd did not significantly affect the RFS and OS in endometrial cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.